Baird R W lowered shares of Bio-Techne (NASDAQ:TECH – Free Report) from a strong-buy rating to a hold rating in a research note published on Wednesday morning,Zacks.com reports. Several other research ...

Bio-Techne (NASDAQ:TECH – Get Free Report) was downgraded by stock analysts at Robert W. Baird from an “outperform” rating to a “neutral” rating in a report issued on Wednesday, Ratings reports. They ...

Headquartered in Minneapolis, Minnesota, Bio-Techne Corporation (TECH) is a leading provider of life sciences solutions ...

Bio-Techne (TECH) announced the launch of an expanded menu of human and mouse RNAscope in situ hybridization probes to advance spatial biology ...

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Bio-Techne Corporation (NASDAQ: TECH), a leading provider of innovative life science research tools, is pleased to announce the official release of GMP Transposase mRNA for the TcBuster™ non-viral ...

Fintel reports that on February 19, 2025, Baird downgraded their outlook for Bio-Techne (NasdaqGS:TECH) from Outperform to ...

Shares of Bio-Techne Corp. TECH slipped 2.25% to $68.34 Tuesday, on what proved to be an all-around positive trading session ...

Baird analyst Catherine Ramsey Schulte downgraded Bio-Techne (TECH) to Neutral from Outperform with a price target of $68, down from $88. The ...

Bio-Techne (NASDAQ: TECH), a global leader in life science tools and reagents, today announced the launch of an expanded menu of human and mouse RNAscope™ in situ hybridization probes to advance ...

Feb 5 (Reuters) - Bio-Techne (TECH.O), opens new tab beat second-quarter profit and revenue estimates on Wednesday, helped by growth in its protein sciences unit that makes products to develop ...

Shares of Bio-Techne Corp. TECH slipped 1.32% to $67.44 Wednesday, on what proved to be an all-around rough trading session ...